Education
About Us
Working with TipRanks
Follow Us
Bioventus, Inc. (BVS)
:BVS
BVS Stock Chart & Stats
$7.00
-$0.12(-1.26%)
At close: 4:00 PM EST
$7.00
-$0.12(-1.26%)
Day’s Range― - ―
52-Week Range$5.81 - $12.61
Previous CloseN/A
Volume116.12K
Average Volume (3M)315.40K
Market Cap
$584.31M
Enterprise Value$798.62M
Total Cash (Recent Filing)$42.16M
Total Debt (Recent Filing)$341.17M
Price to Earnings (P/E)62.2
Beta0.90
Next Earnings
Mar 17, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding66,976,480
10 Day Avg. Volume507,524
30 Day Avg. Volume315,396
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)4.64
Price to Sales (P/S)1.20
P/FCF Ratio18.16
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.42
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda8.90
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.54
Revenue Forecast (FY)$566.83M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCash flow from operations materially increased 71% to nearly $26M, indicating strong financial performance.
Growth StrategyBioventus has set in place levers to drive both short and long-term growth and expects a back-half improvement in its growth rate.
Innovation In Pain TreatmentsThe company is focusing on emerging areas of pain treatments with the potential for significant growth, particularly in PRP and PNS segments.
Bears Say
Bioventus News
BVS FAQ
What was Bioventus, Inc.’s price range in the past 12 months?
Bioventus, Inc. lowest stock price was $5.81 and its highest was $12.61 in the past 12 months.
What is Bioventus, Inc.’s market cap?
Bioventus, Inc.’s market cap is $584.31M.
When is Bioventus, Inc.’s upcoming earnings report date?
Bioventus, Inc.’s upcoming earnings report date is Mar 17, 2026 which is in 117 days.
How were Bioventus, Inc.’s earnings last quarter?
Bioventus, Inc. released its earnings results on Nov 04, 2025. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.105 by $0.045.
Is Bioventus, Inc. overvalued?
According to Wall Street analysts Bioventus, Inc.’s price is currently Overvalued.
Does Bioventus, Inc. pay dividends?
Bioventus, Inc. does not currently pay dividends.
What is Bioventus, Inc.’s EPS estimate?
Bioventus, Inc.’s EPS estimate is 0.2.
How many shares outstanding does Bioventus, Inc. have?
Bioventus, Inc. has 66,976,480 shares outstanding.
What happened to Bioventus, Inc.’s price movement after its last earnings report?
Bioventus, Inc. reported an EPS of $0.15 in its last earnings report, beating expectations of $0.105. Following the earnings report the stock price went up 15.091%.
Which hedge fund is a major shareholder of Bioventus, Inc.?
Currently, no hedge funds are holding shares in BVS
Bioventus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
BVS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 21.1%
Last 30 Days ▲ 21.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.86%
12-Months-Change
Fundamentals
Return on Equity
4.97%
Trailing 12-Months
Asset Growth
-8.82%
Trailing 12-Months
Company Description
Bioventus, Inc.
Bioventus (BVS) is a global leader in the development and commercialization of innovative therapies for musculoskeletal health. The company operates primarily in the orthopedic and pain management sectors, focusing on solutions that enhance healing and improve patient outcomes. Bioventus' core products include its proprietary ultrasound therapy systems, biologic products for joint health, and a range of other advanced medical devices aimed at treating conditions related to bone and soft tissue.
BVS Company Deck
BVS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant organic growth, profitability improvements, and strategic advancements in new markets, alongside effective cash and debt management. The main challenge was the impact of prior divestitures and foreign exchange losses.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
31.90% Insiders
8.43% Mutual Funds
0.16% Other Institutional Investors
51.04% Public Companies and
Individual Investors